These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30373845)

  • 21. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
    Busto R; Schally AV; Varga JL; Garcia-Fernandez MO; Groot K; Armatis P; Szepeshazi K
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11866-71. PubMed ID: 12186980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
    Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of cardiac and systemic function in old mice by agonist of growth hormone-releasing hormone.
    Xiang P; Jing W; Lin Y; Liu Q; Shen J; Hu X; Chen J; Cai R; Hare JM; Zhu W; Schally AV; Yu H
    J Cell Physiol; 2021 Dec; 236(12):8197-8207. PubMed ID: 34224586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
    Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
    Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
    Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
    Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
    Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
    Jimenez JJ; DelCanto GM; Popovics P; Perez A; Vila Granda A; Vidaurre I; Cai RZ; Rick FG; Swords RT; Schally AV
    Br J Haematol; 2018 May; 181(4):476-485. PubMed ID: 29663325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.
    Mezey G; Treszl A; Schally AV; Block NL; Vízkeleti L; Juhász A; Klekner A; Nagy J; Balázs M; Halmos G; Bognár L
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1641-9. PubMed ID: 24878932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.
    Chu WK; Law KS; Chan SO; Yam JC; Chen LJ; Zhang H; Cheung HS; Block NL; Schally AV; Pang CP
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14396-14401. PubMed ID: 27911838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
    Ziegler CG; Ullrich M; Schally AV; Bergmann R; Pietzsch J; Gebauer L; Gondek K; Qin N; Pacak K; Ehrhart-Bornstein M; Eisenhofer G; Bornstein SR
    Mol Cell Endocrinol; 2013 May; 371(1-2):189-94. PubMed ID: 23267837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
    Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.
    Cen LP; Ng TK; Liang JJ; Xu C; Zhuang X; Liu YF; Chen SL; Xu Y; Yang Q; Yuan XL; Qin YJ; Chan SO; Chen H; Zhang M; Schally AV; Pang CP
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.
    Florea V; Majid SS; Kanashiro-Takeuchi RM; Cai RZ; Block NL; Schally AV; Hare JM; Rodrigues CO
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17260-5. PubMed ID: 25404316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.